{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T20:42:03Z","timestamp":1780605723833,"version":"3.54.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"DOI":"10.13039\/501100018936","name":"Universit\u00e4tsklinikum Heidelberg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018936","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n          <jats:p>Ein Patient mit chronischer spontaner Urtikaria (CSU) erhielt eine Behandlung mit dem monoklonalen Antik\u00f6rper Omalizumab, die eine erhebliche klinische Verbesserung bewirkte, jedoch wiederholt schwere anaphylaktische Reaktionen ausl\u00f6ste. Diese traten sowohl nach der Verabreichung des Medikaments als auch w\u00e4hrend eines Prick-Tests auf. Die genauen Mechanismen hinter den Reaktionen sind unklar, m\u00f6gliche Ursachen k\u00f6nnten Zusatzstoffe wie Polysorbat 20\u00a0oder spezifische Antik\u00f6rper sein. Der Fall verdeutlicht das seltene, aber ernste Risiko von Anaphylaxien bei Omalizumab und betont die Notwendigkeit einer engen \u00dcberwachung und Notfallbereitschaft.<\/jats:p>","DOI":"10.1007\/s00105-025-05542-9","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T15:11:54Z","timestamp":1753974714000},"page":"578-580","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Schwere Anaphylaxie auf Omalizumab","Severe anaphylaxis following administration of omalizumab"],"prefix":"10.1007","volume":"76","author":[{"given":"Franziska","family":"Keidel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscila","family":"W\u00f6lbing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knut","family":"Sch\u00e4kel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,31]]},"reference":[{"issue":"7","key":"5542_CR1","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1016\/j.jaip.2019.04.020","volume":"7","author":"TB Casale","year":"2019","unstructured":"Casale\u00a0TB et\u00a0al (2019) Impact of Omalizumab on patient-reported outcomes in chronic idiopathic urticaria: Results from a\u00a0randomized study (XTEND-CIU). J\u00a0Allergy Clin Immunol Pract 7(7):2487\u20132490.e1","journal-title":"J Allergy Clin Immunol Pract"},{"key":"5542_CR2","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.jaci.2007.09.032","volume":"120","author":"L Cox","year":"2007","unstructured":"Cox\u00a0L et\u00a0al (2007) American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. J\u00a0Allergy Clin Immunol 120:1373\u20131377","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"5542_CR3","first-page":"82","volume":"15","author":"R Ertas","year":"2016","unstructured":"Ertas\u00a0R et\u00a0al (2016) Adverse Reaction to Omalizumab in Patients with Chronic Urticaria: Flare Up or Ineffectiveness? Iran J Allergy Asthma Immunol 15(1):82\u201386","journal-title":"Iran J Allergy Asthma Immunol"},{"issue":"3","key":"5542_CR4","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.jaci.2016.03.030","volume":"138","author":"PL Lieberman","year":"2016","unstructured":"Lieberman\u00a0PL et\u00a0al (2016) Anaphylactic reactions associated with omalizumab administration: Analysis of a\u00a0case-control study. J\u00a0Allergy Clin Immunol 138(3):913\u2013915.e2","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"5542_CR5","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1016\/j.jaci.2017.07.013","volume":"140","author":"PL Lieberman","year":"2017","unstructured":"Lieberman\u00a0PL et\u00a0al (2017) Anaphylaxis associated with omalizumab administration: Risk factors and patient characteristics. J\u00a0Allergy Clin Immunol 140(6):1734\u20131736.e4","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"5542_CR6","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/j.jaci.2007.09.022","volume":"120","author":"SL Limb","year":"2007","unstructured":"Limb\u00a0SL et\u00a0al (2007) Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma. J\u00a0Allergy Clin Immunol 120(6):1378\u20131381","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"5542_CR7","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1056\/NEJMoa1215372","volume":"368","author":"M Maurer","year":"2013","unstructured":"Maurer\u00a0M et\u00a0al (2013) Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N\u00a0Engl J Med 368(10):924\u2013935","journal-title":"N Engl J Med"},{"key":"5542_CR8","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2500\/aap.2007.28.3003","volume":"28","author":"KS Price","year":"2007","unstructured":"Price\u00a0KS et\u00a0al (2007) Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy. Allergy Asthma Proc 28:313\u2013319","journal-title":"Allergy Asthma Proc"},{"issue":"3","key":"5542_CR9","first-page":"191","volume":"135","author":"SS Saini","year":"2015","unstructured":"Saini\u00a0SS et\u00a0al (2015) Efficacy and safety of omalizumab in patients with chronic idiopathic\/spontaneous urticaria who remain symptomatic on H1 antihistamines: a\u00a0randomized, placebo-controlled study. J\u00a0Investig Dermatology 135(3):191\u2013198","journal-title":"J Investig Dermatology"},{"key":"5542_CR10","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1159\/000527158","volume":"184","author":"X Song","year":"2023","unstructured":"Song\u00a0X et\u00a0al (2023) Impact of Omalizumab on Anpahylaxis in Patients treated for Chronic Urticaria. Int Arch Allergy Immunol 184:199\u2013201","journal-title":"Int Arch Allergy Immunol"},{"key":"5542_CR11","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/j.1440-1797.2005.00389.x","volume":"10","author":"RH Steele","year":"2005","unstructured":"Steele\u00a0RH et\u00a0al (2005) Hypersensitivity reactions to the polysorbate contained in recombinant erythropoietin and darbepoetin. Nephrol (cariton) 10:317\u2013320","journal-title":"Nephrol (cariton)"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-025-05542-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-025-05542-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-025-05542-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T09:24:18Z","timestamp":1757064258000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-025-05542-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,31]]},"references-count":11,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["5542"],"URL":"https:\/\/doi.org\/10.1007\/s00105-025-05542-9","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"value":"2731-7005","type":"print"},{"value":"2731-7013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,31]]},"assertion":[{"value":"18 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F.\u00a0Keidel, P.\u00a0W\u00f6lbing und K.\u00a0Sch\u00e4kel geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patient\/-innen zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern\/Vertreterinnen eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}